Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05911568

Treatment With Endovascular Intervention for STroke Patients With Existing Disability

TESTED will compare the risks and benefits of endovascular thrombectomy (EVT) to medical management (no EVT) in ischemic stroke patients who have a blockage in one of the large blood vessels in the brain and have a moderate-to-severe disability prior to their stroke.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

HonorHealth, Phoenix, Arizona, United States

Loading trial locations.

About this study

People with disabilities can suffer acute ischemic stroke (AIS). Endovascular clot removal is a breakthrough therapy for large vessel occlusion (LVO) AIS. Pre-stroke disabled patients were excluded from pivotal EVT stroke trials, so whether EVT is effective for those with pre-stroke disability is not known. As a result, two competing, widely-practiced, treatment paradigms have emerged based on individual practitioners' extrapolation of EVT benefits and safety from patients without a pre-stroke disability to those with disability: 1) Multimodal Medical Management (MMM; using intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol lowering medications, and other rehabilitative measures, as indicated) without EVT, and 2) EVT with the background of MMM.

TESTED will enroll patients with LVO-AIS who have a pre-existing disability, defined as pre-stroke modified Rankin score (mRS) 3 and 4, at 12 geographically distinct comprehensive stroke centers serving diverse race-ethnic and socioeconomic populations. The central objective of TESTED is to determine the comparative effectiveness and safety of these two different practice paradigms.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (≥18 years)
  • Moderate-to-severe pre-stroke functional disability, defined as mRS 3-4, for at least 3 months prior to stroke onset
  • Presenting to study hospital within 24 hours of last known well time
  • Diagnosis of acute ischemic stroke
  • Intracranial causative occlusion of the internal carotid artery or the M1 or dominant M2 segments of the middle cerebral artery visualized on the baseline CT(or MR) angiogram
  • Presenting CT Alberta Stroke Program Early CT (ASPECT) score ≥3 or MRI ASPECT score ≥4
  • Presenting NIH Stroke Scale score ≥6
  • Informed consent from patient if competent or from legally authorized representative

Exclusion criteria

  • Known diagnosis of a terminal cancer or terminal illness at the time of stroke
  • Assessment of pre-stroke functional status cannot be performed during the hospital stay
  • Pre-stroke disability deemed temporary in the investigator's opinion (for example, recovering from a general medical illness or traumatic bodily injury)

Treatment and study plan

Endovascular Stroke Treatment

Procedure

Patients who receive endovascular stroke treatment when they are admitted into the hospital, as determined by their clinical care team. Endovascular stroke treatment consist of catheter-based treatment for the blood clot causing the acute ischemic stroke

Medical management

Other

Patients who receive MMM when they are admitted into the hospital, as determined by their clinical care team. MMM may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care. Specifically, this treatment does not involve endovascular stroke treatment.

Primary outcomes

  1. modified Rankin Scale (mRS)

    Time frame: 90 (±14) days after treatment initiation

    Score of 0-3, 4, 5 or 6 on the modified Rankin Scale (mRS) (Note: mRS range: 0 (no residual symptoms) to 6 (death)

Secondary outcomes

  1. Disability-weighted (or utility-weighted) mRS

    Time frame: 90 (±14) days after treatment initiation

    Standard utility weights applied to the mRS categories as follows: 1.0 for mRS level 0; 0.91 for mRS level 1; 0.76 for mRS level 2; 0.65 for mRS level 3; 0.33 for mRS level 4; 0 for mRS level 5; and 0 for mRS level 6

  2. Return to the pre-stroke mRS level

    Time frame: 90 (±14) days after treatment initiation

    Returning to the pre-stroke mRS level post stroke

  3. EQ-5D-5L

    Time frame: 90 (±14) days after treatment initiation

    Quality of life assessment scale with range: 0 (worst health) to 100 (best health)

  4. Academic Medical Center - Linear Disability Scale (ALDS)

    Time frame: 90 (±14) days after treatment initiation

    Generic item bank that measures the disability status of patients with a broad range of diseases, as expressed by the ability to perform activities in daily living.

Other outcomes

  1. modified Rankin Scale (mRS)

    Time frame: At hospital discharge

    Score of 0-3, 4, 5 or 6 on the modified Rankin Scale (mRS) (Note: mRS range: 0 (no residual symptoms) to 6 (death)

  2. Montreal Cognitive Assessment (MoCA)

    Time frame: 90 (±14) days after treatment initiation

    Montreal Cognitive Assessment (MoCA) (Note: MoCA range: 0-30, higher scores mean better outcome)

  3. Barthel Index Scale

    Time frame: 90 (±14) days after treatment initiation

    Barthel Index range: 0-100, higher scores mean participant is independent

  4. Initial residence level or better time during first 90 days post-stroke

    Time frame: 90 days after treatment initiation

    Number of days spend at the initial residence level or better during the first 90 days post-stroke

  5. Zarit's Burden Interview (ZBI)

    Time frame: 90 (±14) days after treatment initiation

    ZBI is a measure of caregiving burden that includes a 22 item interview. Each item on the interview is a statement which the caregiver is asked to endorse using a 5-point scale. Response options range from 0 (Never) to 4 (Nearly Always). We will use the 4 item version of the ZBI which has good correlation with the full version.

  6. Extended Thrombolysis in Cerebral Ischemia scale

    Time frame: At the end of EVT procedure

    The 7-point scale of eTICI is as follows: eTICI0 = 0% reperfusion; eTICI 1 = minimal flow past the occlusion but no perfusion ; eTICI2a = 1-49% reperfusion; eTICI2b50 = 50-66% reperfusion; eTICI2b67 = 67-89% reperfusion; eTICI2c = 90-99% reperfusion; eTICI3 = complete reperfusion

  7. Death

    Time frame: 90 (±14) after treatment initiation

  8. Symptomatic intracranial hemorrhage

    Time frame: 24 (±6) hours

    Evaluate modified Heidelberg definition

Study contacts

Contact information is provided by the study sponsor or research team.

Eva Mistry, MD

CONTACT

[email protected]

513-558-1291

Naima Griffin

CONTACT

[email protected]

513-558-0125

Sponsors and collaborators

Lead sponsor

University of Cincinnati

Other

Collaborators

  • Icahn School of Medicine at Mount Sinai
  • Patient-Centered Outcomes Research Institute
  • University of California, Los Angeles

Registry information

Acronym: TESTED

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
Jun 22, 2023
Registry last updated
Apr 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.